17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation

被引：50
|
作者：
Dijkstra, M. K. [1 ]
van Lom, K. [1 ]
Tielemans, D. [2 ]
Elstrodt, F. [3 ]
Langerak, A. W. [2 ]
van't Veer, M. B. [1 ]
Jongen-Lavrencic, M. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Immunol, Rotterdam, Netherlands
[3] Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Med Oncol, Rotterdam, Netherlands
来源：
LEUKEMIA | 2009年 / 23卷 / 03期
关键词：
TUMOR-SUPPRESSOR;
D O I：
10.1038/leu.2008.264
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：625 / 627
页数：4
相关论文
共 50 条
  • [1] 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
    M K Dijkstra
    K van Lom
    D Tielemans
    F Elstrodt
    A W Langerak
    M B van ‘t Veer
    M Jongen-Lavrencic
    Leukemia, 2009, 23 : 625 - 627
  • [2] p53 Immunohistochemistry Predicts 17p13(TP53) Deletion in CLL
    Jiang, A.
    Qi, C.
    Chang, H.
    MODERN PATHOLOGY, 2009, 22 : 269A - 269A
  • [3] p53 Immunohistochemistry Predicts 17p13(TP53) Deletion in CLL
    Jiang, A.
    Qi, C.
    Chang, H.
    LABORATORY INVESTIGATION, 2009, 89 : 269A - 269A
  • [4] MICRORNA-34A IS SIGNIFICANTLY DOWN-REGULATED IN B-CLL PATIENTS WITH P53 ABNORMALITIES
    Mraz, M.
    Kotaskova, J.
    Tichy, B.
    Malinova, K.
    Trbusek, M.
    Brychtova, Y.
    Mayer, J.
    Pospisilova, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 213 - 213
  • [5] TP53 Protein Expression, But Not 17p13 Deletion, is Useful in Rapid Screening and Triage of TP53 Mutation in Acute Myeloid Leukemia
    Nwaoduah, Nneamaka
    Bernabeu, Belen Quereda
    Wang, Zixuan
    Liu, Jinglan
    Uppal, Guldeep
    Peiper, Stephen
    Gong, Jerald
    LABORATORY INVESTIGATION, 2018, 98 : 541 - 541
  • [6] TP53 Protein Expression, But Not 17p13 Deletion, is Useful in Rapid Screening and Triage of TP53 Mutation in Acute Myeloid Leukemia
    Nwaoduah, Nneamaka
    Bernabeu, Belen Quereda
    Wang, Zixuan
    Liu, Jinglan
    Uppal, Guldeep
    Peiper, Stephen
    Gong, Jerald
    MODERN PATHOLOGY, 2018, 31 : 541 - 541
  • [7] Bacterial artificial chromosome (BAC) array CGH study of B-CLL patients with 17p13 deletion.
    Brito-Babapulle, V
    Rudenko, H
    Dearden, C
    Fenwick, K
    McKay, A
    Ashworth, A
    Matutes, E
    Catovsky, D
    Morgan, G
    BLOOD, 2005, 106 (11) : 597A - 597A
  • [8] Genetic aberrations in a prospective randomized B-CLL trial:: Deletion 17p13 (p53) predicts for nonresponse to fludarabine.
    Stilgenbauer, S
    Rummel, M
    Bullinger, L
    Kröber, A
    Lichter, P
    Bergmann, L
    Döhner, H
    BLOOD, 2000, 96 (11) : 515A - 515A
  • [9] Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma
    Tian, Erming
    Epstein, Joshua
    Qu, Pingping
    Heuck, Christoph
    van Rhee, Frits
    Zangari, Maurizio
    Hoering, Antje
    Sawyer, Jeffery
    Barlogie, Bart
    Morgan, Gareth J.
    BLOOD, 2015, 126 (23)
  • [10] Clonal evolution in B-CLL:: Acquisition of deletions involving 6q21, 11q22 and 17p13 (TP53) associated with disease progression.
    Leupolt, E
    Stilgenbauer, S
    Kröber, A
    Bullinger, L
    Lichter, P
    Döhner, H
    BLOOD, 2001, 98 (11) : 471A - 471A
12345